交联可调式抗结核药物缓释型纳米人工骨复合体的生物安全性研究

Biological security of sustained-release artificial bone composite of cross-linked adjustable anti-tuberculosis drugs

目的研究交联可调式抗结核药物缓释型纳米人工骨复合体的生物安全性。方法对交联可调式抗结核药物缓解型纳米人工骨复合体进行MTT细胞毒性实验、急性全身毒性实验、皮内刺激实验及致敏实验,并与对照组比较。结果该交联可调式抗结核药物缓解型纳米人工骨复合体MTT细胞毒性实验显示人工骨材料细胞存活率>90%,细胞毒性1级。人工骨复合材料浸取液未引起豚鼠过敏。小鼠尾静脉注射后未出现明显全身毒性反应。结论交联可调式抗结核药物缓释型纳米人工骨复合材料无MTT细胞毒性,细胞相容性良好,并能够降低利福平直接给药的生物毒性,不引起全身毒性反应、皮肤/内刺激反应和急性过敏反应,具有良好的生物安全性。

Objective To investigate the biological security of sustained-release artificial bone composite of cross-linked adjustable anti-tuberculosis drugs.Methods MTT toxicity test,acute systemic toxicity test,intracutaneous irritation test and skin sensitization in stimulation were performed in the sustained-release artificial bone composite of cross-linked adjustable anti-tuberculosis drugs.The results were compared with control group.Results MTT toxicity test showed that the survival rate of bone cells in artificial materials was more than 90% and cytotoxicity was on grade 1.Artificial bone composite liquid did not cause allergic reaction in guinea pig.No obvious systemic toxic reaction was found in mice after intravenous injection.Conclusion There is no MTT cytotoxicity in the sustained-release artificial bone composite of cross-linked adjustable anti-tuberculosis drugs.It can reduce the biological toxicity of rifampicine and will not cause systemic toxic reaction,skin/hypodermic stimulation reactions and acute allergic reaction.It has good cell compatibility and biological security.